Bicalutamide dosages used in the treatment of prostate cancer

比卡鲁胺 抗雄激素 氟他胺 前列腺癌 医学 耐受性 雄激素 雄激素受体 封锁 内科学 内分泌学 泌尿科 睾酮(贴片) 雄激素剥夺疗法 二氢睾酮 促黄体激素 药理学 癌症 激素 不利影响 受体
作者
Geert J.C.M. Kolvenbag,Anthony F Nash
出处
期刊:The Prostate [Wiley]
卷期号:39 (1): 47-53 被引量:49
标识
DOI:10.1002/(sici)1097-0045(19990401)39:1<47::aid-pros8>3.0.co;2-x
摘要

Androgen deprivation is often used for the treatment of patients with prostate cancer. Androgen deprivation can be achieved by surgical castration or medical castration, with or without using an antiandrogen. Each of these treatments may be used alone, or an antiandrogen may be used alongside castration to produce combined androgen blockade therapy.The nonsteroidal antiandrogen, bicalutamide (Casodex), has been evaluated as a component in combined androgen blockade and as monotherapy. We review the arguments that indicate why a 50-mg once-daily dose of bicalutamide is appropriate in combined androgen blockade, while ongoing clinical trials evaluate 150-mg once-daily as monotherapy in the treatment of prostate cancer.The choice of the 50-mg dose of bicalutamide when used in combined androgen blockade is supported by four main arguments. First, bicalutamide 50 mg is at least equivalent to, if not better than, flutamide 750 mg in terms of receptor affinity, potency, and favorable plasma concentration profile. Second, the reduction in testosterone concentrations produced by medical or surgical castration decreases the potential competition between bicalutamide and testosterone for androgen receptors in prostate cells, allowing the use of a lower dose of antiandrogen in combined androgen blockade than is necessary in monotherapy. Third, bicalutamide 50 mg has an excellent tolerability profile. Fourth, at the 50-mg dose, bicalutamide plus luteinizing hormone-releasing hormone analogue was equivalent to flutamide plus luteinizing hormone-releasing hormone analogue, although there was a trend towards longer survival with bicalutamide. Furthermore, investigations of higher doses of bicalutamide have justified evaluation of bicalutamide 150 mg as monotherapy. First, pharmacodynamic studies reveal an increasing prostate-specific antigen response with increasing dose, which appears to plateau at a dose of around 150-200 mg. Second, in an analysis with 31% mortality, bicalutamide 150 mg appeared to have equivalent efficacy compared with castration in terms of survival in patients with nonmetastatic prostate cancer.On the basis of available data, bicalutamide 50 mg is an appropriate dose to use in combined androgen blockade, while 150 mg is being evaluated in ongoing clinical trials as a suitable dose for monotherapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
付小肥完成签到,获得积分20
刚刚
俞安珊完成签到,获得积分10
1秒前
Ireneeee完成签到 ,获得积分10
1秒前
jenna完成签到,获得积分10
1秒前
研友_VZG7GZ的应助被郭立裕采纳,获得10
1秒前
1秒前
马骁完成签到,获得积分10
1秒前
2秒前
2秒前
Ava的应助被深情雨泽采纳,获得10
2秒前
奶思兔米鱿完成签到 ,获得积分10
2秒前
阳光的冬天完成签到,获得积分10
2秒前
芙蕖星星发布了新的文献求助50
2秒前
小小小先生的应助被时不渡我采纳,获得10
2秒前
send完成签到,获得积分10
3秒前
科目三的应助被疯狂求助文献采纳,获得10
3秒前
精明纸飞机完成签到,获得积分10
3秒前
4秒前
小yu发布了新的文献求助20
5秒前
科研通AI6.2的应助被背锅侠采纳,获得10
5秒前
5秒前
点凌蝶完成签到,获得积分10
5秒前
荷序发布了新的文献求助10
5秒前
Xuech完成签到,获得积分10
6秒前
碎觉觉发布了新的文献求助30
6秒前
屁屁伽完成签到 ,获得积分10
6秒前
6秒前
7秒前
赴山珩完成签到,获得积分10
7秒前
胖虎完成签到,获得积分10
7秒前
钟爱小奏完成签到,获得积分10
8秒前
秦奎完成签到,获得积分10
8秒前
wxtlzzdp发布了新的文献求助10
9秒前
阳光的水壶完成签到,获得积分10
10秒前
shiyi11完成签到,获得积分10
10秒前
xxt完成签到,获得积分10
10秒前
雷家完成签到,获得积分10
10秒前
感动的早晨完成签到,获得积分20
10秒前
Lin发布了新的文献求助10
10秒前
senquana完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180407
求助须知:如何正确求助?哪些是违规求助? 9570403
关于积分的说明 21811831
捐赠科研通 7776452
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557499
邀请新用户注册赠送积分活动 2479105